Appeal finds NICE decision on £90k breast cancer drug 'unfair'
The impact of the government’s drug pricing deal on patient access to new medicines has been thrown into confusion after a pharmaceutical company’s appeal against the decision to ban routine NHS funding of one of its drugs was upheld.
You need to be a subscriber to read more
Subscribe for unlimited access
With a HSJ subscription you’ll unlock:
- All HSJ news by sector, topic & region
- Breaking News announcements
- App for mobile and offline reading
- Comment and Daily Insights newsletters
- Regional roundup newsletters
- Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
- 10 expert briefings every fortnight (Premium only)
Already a subscriber? Sign into your account here